株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

胃潰瘍 : パイプライン分析

Gastric Ulcers - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 246014
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
胃潰瘍 : パイプライン分析 Gastric Ulcers - Pipeline Review, H2 2016
出版日: 2016年09月14日 ページ情報: 英文 43 Pages
概要

胃潰瘍は胃の内壁における有痛性のびらんまたは潰瘍です。胃潰瘍の最も一般的な原因はヘリコバクター・ピロリ菌感染です。症状には疼痛、腫脹感、吐き気、悪心または嘔吐、および原因不明の体重減少です。素因には喫煙およびアルコール依存などが含まれます。治療には抗生物質および制酸剤などが用いられます。

当レポートでは、胃潰瘍に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

胃潰瘍の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • アステラス製薬
  • ChoDang Pharm Co., Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Priaxon AG
  • Sihuan Pharmaceutical Holdings Group Ltd.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • 300-PXN-0040
  • Anaprazole Sodium
  • ASP-6537
  • DWJ-206
  • PMKS-005
  • PRD-007
  • 小分子治療薬

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8458IDB

Summary

Global Markets Direct's, 'Gastric Ulcers - Pipeline Review, H2 2016', provides an overview of the Gastric Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers
  • The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects
  • The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Gastric Ulcers

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastric Ulcers Overview
  • Therapeutics Development
    • Pipeline Products for Gastric Ulcers - Overview
  • Gastric Ulcers - Therapeutics under Development by Companies
  • Gastric Ulcers - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Gastric Ulcers - Products under Development by Companies
  • Gastric Ulcers - Companies Involved in Therapeutics Development
    • Ache Laboratorios Farmaceuticos S/A
    • Astellas Pharma Inc.
    • ChoDang Pharm Co., Ltd.
    • Kukje Pharmaceutical Industry Co., Ltd.
    • XuanZhu Pharma Co., Ltd.
  • Gastric Ulcers - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ecabet + ranitidine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anaprazole sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KJ-14001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDI-39 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMKS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Gastric Ulcers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gastric Ulcers - Dormant Projects
  • Gastric Ulcers - Discontinued Products
  • Gastric Ulcers - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
      • Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
      • Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
      • Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
      • Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
      • Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
      • Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court
      • Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
      • Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals
      • Oct 23, 2001: Prilosec US litigation
      • May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec
      • May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent
      • Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement
      • Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada
      • Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastric Ulcers, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Gastric Ulcers - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Gastric Ulcers - Pipeline by Astellas Pharma Inc., H2 2016
  • Gastric Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H2 2016
  • Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016
  • Gastric Ulcers - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Gastric Ulcers - Dormant Projects, H2 2016
  • Gastric Ulcers - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Gastric Ulcers, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top